Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (27982)	2/7/1999 4:34:00 PM
From: Mudcat	Respond to of 32384

TD, if the company has something worth while (science or product) that will sell, someone will buy the stock. It appears (although I know nothing about Shaman) that these companies expended all their funds and buyers determined that it was not worth while to put further funds into these companies because they could not produce what they trying to. Lgnd is not in this category at this time. Lgnd now had approved drugs and time will tell if anyone will buy these drugs. Let me say this, if these approved drugs do not sell and the breast cancer trials in humans for Targretin do not prove conclusive, then Lgnd will become one of these biotechs where the stock price plummets to practically nothing of value.